ABSTRACT
Background and Purpose Cognitive impairment has been linked to poor motor learning and rehabilitation outcomes in older adult and stroke populations, but this remains unexplored in individuals with Parkinson disease (PD). The purpose of this secondary data analysis from a recent clinical trial (NCT02600858) was to determine if global cognition was related to nine-day skill retention after upper-extremity motor training in individuals with PD.
Methods Twenty-three participants with idiopathic PD completed three consecutive days of training on an upper-extremity task. For the purposes of the original clinical trial, participants trained either “on” or “off” their dopamine replacement medication. Baseline, training, and shorter-term (48-hour) retention data have been previously published. Global cognition was evaluated using the Montreal Cognitive Assessment (MoCA). Participant age, baseline performance, MoCA score, and group (medication “on”/”off”) were included in a multivariate linear regression model to predict longer-term (nine day) follow-up performance. Baseline and follow-up performance were assessed for all participants while “on” their medication.
Results MoCA score was positively related to follow-up performance, such that individuals with better cognition performed better than those with poorer cognition. Participant age, baseline performance, and medication status were unrelated to follow-up performance.
Discussion and Conclusions Results of this secondary analysis align with previous work that suggest cognitive impairment may interfere with motor learning in PD, and that assessing cognition could provide prognostic information about an individual’s responsiveness to motor rehabilitation for a number of clinical populations.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02600858
Funding Statement
This work was supported in part by the National Institute on Aging at the National Institutes of Health (K01 AG047926 to SYS and F31 AG062057 to JLV); University of Utah Office of Research (2015-16 grant), USA; the American Parkinson Disease Association (2015-16 postdoctoral fellowship grant).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Utah IRB approved all experimental protocols for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest and Source of Funding: The authors have no conflict of interests to report, financial or otherwise. This work was supported in part by the National Institute on Aging at the National Institutes of Health (K01 AG047926 to SYS and F31 AG062057 to JLV); University of Utah Office of Research (2015-16 grant), USA; the American Parkinson Disease Association (2015-16 postdoctoral fellowship grant).
This work is a secondary analysis of a previously published clinical trial (clinicaltrial.gov registration number NCT02600858) and has not been presented in scientific meetings nor publications.
Data Availability
All data will be made available upon reasonable request.
